Bristol-Myers Squibb can probably continue to grow for a long time. Its dividend looks to be sustainable at the moment. But ...

In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...

Artificial intelligence is changing the way industries do business. But executives in the pharmaceutical industry are still ...

The moves will affect more than 300 employees across both companies as both firms look to drive growth in the long term.

Shares of Purple Biotech ($PPBT) surged more than 45% on Monday morning, reaching their highest levels since early October.

Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics ...

Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold ...

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...